News Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq 23:00:00 09/09/2026 +03			5-day change	1st Jan Change
521.12 ^USD	-1.47%		-6.40%	+14.95%

09-02	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
09-01	Vertex Pharmaceuticals Incorporated Announces Chief Financial Officer Changes, Effective January 1, 2027	CI

All News

Mentions Relevance

09-02	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
09-01	Vertex Pharmaceuticals Incorporated Announces Chief Financial Officer Changes, Effective January 1, 2027	CI
09-01	Vertex Pharmaceuticals Incorporated Appoints Jonathan Poole as Executive Vice President, Effective January 1, 2027	CI
09-01	Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes	DJ
09-01	Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition	MT
09-01	Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team	BU
08-26	Vertex to Participate in Upcoming September Investor Conferences	BU
08-12	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
08-11	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT
08-11	Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $556 From $555, Maintains Buy Rating	MT
08-10	Vertex Shares Rise as Rival Sionna's Cystic-Fibrosis Trial Fails to Meet Endpoint	DJ
08-10	Sionna scraps genetic disorder drug program after trial setback; shares tank	RE
08-05	Rothschild & Co Redburn Adjusts Vertex Pharmaceuticals Price Target to $580 From $570	MT
08-05	Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q)	PU
08-04	Tranche Update on Vertex Pharmaceuticals Incorporated's Equity Buyback Plan announced on May 19, 2025.	CI
08-04	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says	MT
08-04	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT
08-04	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
08-04	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT
08-04	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $653 From $652, Maintains Buy Rating	MT
08-04	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $500 From $466, Maintains Hold Rating	MT
08-04	Cantor Fitzgerald Adjusts PT on Vertex Pharmaceuticals to $595 From $590, Maintains Overweight Rating	MT
08-04	Canaccord Genuity Adjusts PT on Vertex Pharmaceuticals to $442 From $436, Maintains Hold Rating	MT
08-04	TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
08-04	Vertex Pharmaceuticals Incorporated, Q2 2026 Earnings Call, Aug 03, 2026